ArticleScientific reports2025
Integrated analysis of Corylin from Psoralea Corylifolia inhibiting osteoporosis via MAPK pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- DNA Methylation, SERPING1 Expression, and Immune-related Traits in Osteoporosis: A Mendelian Randomization Study And SupportiveEndocrine, metabolic & immune disorders drug targets · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Corylin, a natural flavonoid from Psoralea corylifolia (PC), has shown promise in the treatment of osteoporosis (OP) but the underlying mechanisms are unclear. This study aims to elucidate these mechanisms using network pharmacology, bioinformatics, molecular docking and in vitro experiments. Firstly, 213 potential therapeutic targets and 44 key targets were identified. Using the CytoHubba plugin, we screened the top 10 hub genes, including MMP9, BCL2, PPARG, PTGS2 and TNF, and others. Secondly, we identified that the MAPK, HIF-1, and Ras signaling pathways were highly enriched through enrichment analysis. The high enrichment of the MAPK pathway was further validated through transcriptomic analysis. Additionally, molecular dynamic simulation verified the formation of stable complexes between corylin and MMP9, PPARG, and PTGS2. Finally, we conducted in vivo and in vitro experiments to verify the effects of corylin on OP. In vitro, corylin (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.